PTCT Stock Analysis: PTC Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.850m USD | 12M Return: 32.6% | US69366J2006 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 61.2M
Qual. Beats: 0
Rev. Trend: 43.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
PTC Therapeutics, Inc. is a U.S.-based biopharmaceutical company headquartered in Warren, New Jersey, that discovers, develops, and commercializes treatments for rare disorders globally. Its marketed portfolio includes Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza (marketed as Kebilidi in the U.S.) for AADC deficiency, Tegsedi and Waylivra for rare diseases, and Evrysdi for spinal muscular atrophy.
The companys development pipeline targets additional rare conditions, including Sepiapterin for phenylketonuria, PTC518 for Huntingtons disease, and vatiquinone for Friedreichs ataxia, supported by platforms in splicing, inflammation, and ferroptosis. As a rare disease specialist, PTC relies on third-party distributors for product delivery and maintains strategic collaborations and licensing agreements with major partners such as Roche, Novartis, the SMA Foundation, and Akcea Therapeutics.
- DMD franchise Translarna and Emflaza sales face regulatory headwinds
- Evrysdi SMA royalties from Roche expand as prescriptions grow
- PTC518 Huntingtons program milestone payments from Novartis advance
| Net Income: -38.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA -33.01 > 1.0 |
| NWC/Revenue: 183.0% < 20% (prev 93.21%; Δ 89.82% < -1%) |
| CFO/TA -0.01 > 3% & CFO -30.5m > Net Income -38.4m |
| Net Debt (270.9m) to EBITDA (173.5m): 1.56 < 3 |
| Current Ratio: 3.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.0m) vs 12m ago 17.75% < -2% |
| Gross Margin: 82.14% > 18% (prev 97.09%; Δ -14.95% > 0.5%) |
| Asset Turnover: 34.28% > 50% (prev 67.00%; Δ -32.72% > 0%) |
| Interest Coverage Ratio: 0.64 > 6 (EBIT TTM 118.2m / Interest Expense TTM 185.3m) |
| A: 0.57 (Total Current Assets 2.62b - Total Current Liabilities 771.1m) / Total Assets 3.25b |
| B: -0.89 (Retained Earnings -2.88b / Total Assets 3.25b) |
| C: 0.04 (EBIT TTM 118.2m / Avg Total Assets 2.94b) |
| D: -0.05 (Book Value of Equity -165.4m / Total Liabilities 3.42b) |
| Altman-Z'' = 1.05 = BB |
| DSRI: 2.13 (Receivables 239.0m/196.1m, Revenue 1.01b/1.76b) |
| GMI: 1.18 (GM 97.09% / 82.14%) |
| AQI: 1.66 (AQ_t 0.16 / AQ_t-1 0.09) |
| SGI: 0.57 (Revenue 1.01b / 1.76b) |
| TATA: -0.00 (NI -38.4m - CFO -30.5m) / TA 3.25b) |
| Beneish M = -1.85 (Cap -4..+1) = B |
As of September 01, 2026, the stock is trading at USD 69.54 with a total of 841,095 shares traded. Over the past week, the price has changed by -2.14%, over one month by +2.25%, over three months by -5.77% and over the past year by +32.63%.
Current recommended Stop Loss: 66.90 (which is 3.8% or 1.1 ATR below the current price).
PTC Therapeutics has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy PTCT.
- StrongBuy: 5
- Buy: 4
- Hold: 4
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 99.3 | 42.8% |
P/E Forward = 39.6825
P/S = 5.799
P/B = 1743.2734
P/EG = 0.81
Revenue TTM = 1.01b USD
EBIT TTM = 118.2m USD
EBITDA TTM = 173.5m USD
Long Term Debt = 535.5m USD (from longTermDebt, last quarter)
Short Term Debt = 73.4m USD (from shortTermDebt, last quarter)
Debt = 802.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 105.5m
Net Debt = 270.9m USD (calculated: Debt 802.0m - CCE 531.1m)
Enterprise Value = 6.12b USD (5.85b + Debt 802.0m - CCE 531.1m)
Interest Coverage Ratio = 0.64 (Ebit TTM 118.2m / Interest Expense TTM 185.3m)
EV/FCF = -30.53x (Enterprise Value 6.12b / FCF TTM -200.5m)
FCF Yield = -3.28% (FCF TTM -200.5m / Enterprise Value 6.12b)
FCF Margin = -19.87% (FCF TTM -200.5m / Revenue TTM 1.01b)
Net Margin = -3.80% (Net Income TTM -38.4m / Revenue TTM 1.01b)
Gross Margin = 82.14% ((Revenue TTM 1.01b - Cost of Revenue TTM 180.2m) / Revenue TTM)
Gross Margin QoQ = 94.47% (prev 89.72%)
Tobins Q-Ratio = 1.88 (Enterprise Value 6.12b / Total Assets 3.25b)
Interest Expense / Debt = 23.10% (Interest Expense 185.3m / Debt 802.0m)
Taxrate = 14.40% (14.0m / 97.5m)
NOPAT = 101.2m (EBIT 118.2m * (1 - 14.40%))
Current Ratio = 3.23 (Total Current Assets 2.62b / Total Current Liabilities 811.5m)
Debt / Equity = -4.85 (negative equity) (Debt 802.0m / totalStockholderEquity, last quarter -165.4m)
Debt / EBITDA = 1.56 (Net Debt 270.9m / EBITDA 173.5m)
Debt / FCF = -1.35 (negative FCF - burning cash) (Net Debt 270.9m / FCF TTM -200.5m)
Total Stockholder Equity = -176.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.30% (Net Income -38.4m / Total Assets 3.25b)
RoE = 21.72% (negative equity) (Net Income TTM -38.4m / Total Stockholder Equity -176.7m)
RoCE = 32.95% (EBIT 118.2m / Capital Employed (Equity -176.7m + L.T.Debt 535.5m))
RoIC = 4.04% (NOPAT 101.2m / Invested Capital 2.50b)
WACC = 8.95% (E(5.85b)/V(6.65b) * Re(7.47%) + D(802.0m)/V(6.65b) * Rd(23.10%) * (1-Tc(0.14)))
Discount Rate = 7.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.44 | Cagr: 8.56%
[DCF] Fair Price = unknown (Cash Flow -200.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.28 | # QB: 0
Revenue Correlation: 43.94 | Revenue CAGR: 18.31% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.31 | Chg30d=-42.24% | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=1.60 | Chg30d=+7.16% | Revisions=+40% | GrowthEPS=-79.0% | GrowthRev=-27.5%
EPS next Year (2027-12-31): EPS=2.50 | Chg30d=-19.01% | Revisions=+17% | GrowthEPS=+56.6% | GrowthRev=+9.1%
[Analyst] Revisions Ratio: +10% (up=4, down=3)